SPPI - Spectrum Pharma up 5% after-hours following quarterly earnings beat

Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) are up 5% in after-hours trading after beating Q3 2021 EPS estimates. On a GAAP basis, the company's net loss in the quarter narrowed ~32% year over year to $33.1M (-$0.21 per basic and diluted share). The company ended the quarter with $133.6M in cash. In the pipeline, Spectrum said it is on schedule with an NDA submission of poziotinib for non-small cell lung cancer by the end of the year. Also, following a Type A meeting with the FDA for Rolontis (eflapegrastim), a long-acting, granulocyte colony-stimulating factor for neutropenia, remediation efforts should be completed by year end with an NDA resubmission to shortly follow.

For further details see:

Spectrum Pharma up 5% after-hours following quarterly earnings beat